Evidence map›Paper›PMID 1833083›Full record

ReviewCancer metastasis reviews1991

Integrin expression in malignant melanoma.

R H Kramer, M Vu, Y F Cheng, D M Ramos

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer metastasis reviews, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

R H KramerDepartment of Stomatology, University of California, San Francisco.
M Vu
Y F Cheng
D M Ramos
University of California, San Francisco · US

Funding

TUMOR CELL INVASION OF MICROVESSEL SUBENDOTHELIAL MATRIXR01CA033834 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI KRAMER, RANDALL H · 1985 to 1992
–
INTEGRIN RECEPTOR FOR LAMININ IN MALIGNANT MELANOMAR01CA051884 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI KRAMER, RANDALL H · 1990 to 1994
–
NCI NIH HHS CA 33834NCI NIH HHS CA 51884
6 · The paper itself

Abstract

Invasion of melanoma cells into the underlying interstitial stromal matrix is the initial step for subsequent local and distant metastasis. The invading tumor cell must interact with the extracellular matrix during the early stages of invasion and later during penetration of lymphatic and blood vessels. This interaction with different types of extracellular matrix predicts that the invasive cell must possess surface adhesion receptors with diverse ligand specificities, including the capacity to bind different types of collagens and adhesive glycoproteins. Metastatic melanoma cells do in fact express multiple adhesion receptors, including several of the receptors from the integrin family of heterodimers. The integrin receptors can be either extremely specific for a single ligand or capable of binding multiple ligands. It is likely that the tumor cell's repertoire of adhesion receptors may influence not only its adhesive properties but its metastatic characteristics as well. There is evidence that normal melanocytes have an integrin profile distinct from that of melanoma cells. In particular, melanocytes adhere poorly to laminin while metastatic melanoma cells bind well to this ligand. This difference in adhesion between the two cell types appears to reflect the fact that melanoma cells express a melanoma-specific integrin (alpha 7 beta 1) that binds laminin and is not detectable in normal melanocytes. The presence of increased laminin receptors and enhanced laminin binding in melanoma cells may contribute to the malignant phenotype.

Indexed as

AnimalsCell AdhesionHumansIntegrinsMelanocytesMelanomaMiceNeoplasm InvasivenessNeoplasm MetastasisReceptors, ImmunologicReceptors, LamininIntegrinsReceptors, ImmunologicReceptors, Laminin

Identifiers

PMID1833083
OpenAlexW2055206234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.